ATE469217T1 - Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle - Google Patents

Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle

Info

Publication number: ATE469217T1
Authority: AT; Austria
Prior art keywords: metabolism; amino acid; acid sequence; calcification; activity
Prior art date: 2000-08-11

Application number

AT01958379T

Other languages

English (en)

Inventor

Takeyoshi Yamashita

Takashi Shimada

Satoru Mizutani

Seiji Fukumoto

Original Assignee

Kyowa Hakko Kirin Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-11

Filing date

2001-08-10

Publication date

2010-06-15

2001-08-10 Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd

2010-06-15 Application granted granted Critical

2010-06-15 Publication of ATE469217T1 publication Critical patent/ATE469217T1/de

Links

229920001184 polypeptide Polymers 0.000 title abstract 6
102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title 2
230000004060 metabolic process Effects 0.000 title 2
229910000147 aluminium phosphate Inorganic materials 0.000 title 1
230000002308 calcification Effects 0.000 title 1
230000003913 calcium metabolism Effects 0.000 title 1
229940088594 vitamin Drugs 0.000 title 1
229930003231 vitamin Natural products 0.000 title 1
235000013343 vitamin Nutrition 0.000 title 1
239000011782 vitamin Substances 0.000 title 1
150000003722 vitamin derivatives Chemical class 0.000 title 1
125000003275 alpha amino acid group Chemical group 0.000 abstract 10
230000000694 effects Effects 0.000 abstract 6
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 4
150000001413 amino acids Chemical class 0.000 abstract 4
208000029663 Hypophosphatemia Diseases 0.000 abstract 2
229910019142 PO4 Inorganic materials 0.000 abstract 2
229930003316 Vitamin D Natural products 0.000 abstract 2
QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 2
238000007792 addition Methods 0.000 abstract 2
230000037430 deletion Effects 0.000 abstract 2
238000012217 deletion Methods 0.000 abstract 2
238000001727 in vivo Methods 0.000 abstract 2
230000001939 inductive effect Effects 0.000 abstract 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 2
239000010452 phosphate Substances 0.000 abstract 2
238000006467 substitution reaction Methods 0.000 abstract 2
235000019166 vitamin D Nutrition 0.000 abstract 2
239000011710 vitamin D Substances 0.000 abstract 2
150000003710 vitamin D derivatives Chemical class 0.000 abstract 2
229940046008 vitamin d Drugs 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Microbiology (AREA)
Obesity (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Cell Biology (AREA)
Plant Pathology (AREA)
Diabetes (AREA)
Nutrition Science (AREA)
Urology & Nephrology (AREA)

AT01958379T 2000-08-11 2001-08-10 Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle ATE469217T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP2000245144		2000-08-11
JP2000287684		2000-09-21
JP2000391077		2000-12-22
JP2001121527		2001-04-19
PCT/JP2001/006944 WO2002014504A1 (en)	2000-08-11	2001-08-10	Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same

Publications (1)

Publication Number	Publication Date
ATE469217T1 true ATE469217T1 (de)	2010-06-15

Family

ID=27481531

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01958379T ATE469217T1 (de)	2000-08-11	2001-08-10	Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle

Country Status (12)

Country	Link
US (2)	US20040082506A1 (de)
EP (2)	EP2233571B1 (de)
JP (1)	JP4799801B2 (de)
KR (1)	KR100886276B1 (de)
CN (2)	CN100387713C (de)
AT (1)	ATE469217T1 (de)
AU (2)	AU2001280096B2 (de)
CA (1)	CA2418802C (de)
DE (1)	DE60142239D1 (de)
ES (2)	ES2398203T3 (de)
TW (1)	TWI224620B (de)
WO (1)	WO2002014504A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7833529B1 (en)	1999-01-07	2010-11-16	Zymogenetics, Inc.	Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
EP2233571B1 (de) *	2000-08-11	2012-11-07	Kyowa Hakko Kirin Co., Ltd.	Den Phosphorsäure-Metabolismus, den Kalzium-Metabolismus, Verkalkung und den Vitamin D-Metabolismus kontrollierende Polypeptide sowie für diese kodierende DNA-Moleküle
US7226749B2 (en)	2000-12-05	2007-06-05	Zahradnik Richard J	Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
US6838264B2 (en)	2000-12-05	2005-01-04	Immutopics, Inc.	Antibodies and peptide antigens for producing antibodies having a selective binding specificity to bioactive intact parathyroid hormone (PTH) 1-84
BRPI0209933B8 (pt)	2001-05-24	2021-05-25	Zymogenetics Inc	proteína de fusão, e, molécula de ácido nucleico
JP4527982B2 (ja) *	2001-12-28	2010-08-18	協和発酵キリン株式会社	線維芽細胞増殖因子−２３に対する抗体
US7094551B2 (en)	2002-09-17	2006-08-22	Zahradnik Richard J	Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
JP4633552B2 (ja) *	2005-06-22	2011-02-16	株式会社テクノメディカ	腎臓機能コントロール状態測定方法及び測定システム
EP1922080A2 (de)	2005-08-09	2008-05-21	ZymoGenetics, Inc.	Verfahren zur behandlung von b-zell-malignomen mittels taci-ig-fusionsmolekül
BRPI0711823A2 (pt)	2006-05-15	2012-01-17	Ares Trading Sa	métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
US8012694B2 (en)	2006-09-14	2011-09-06	Immutopics, Inc.	Assay for the detection of phosphorylated PTH
US7883705B2 (en)	2007-02-14	2011-02-08	Kyowa Hakko Kirin Co., Ltd.	Anti FGF23 antibody and a pharmaceutical composition comprising the same
WO2009133905A1 (ja) *	2008-04-28	2009-11-05	協和発酵キリン株式会社	ヒト線維芽細胞増殖因子23（ヒトfgf23)の作用を抑制するペプチドおよびそれを含む医薬組成物
CN101891814B (zh) *	2009-05-21	2012-11-07	中国科学院上海生命科学研究院	抗骨桥蛋白opn单克隆抗体及其应用
WO2012050673A1 (en) *	2010-10-14	2012-04-19	Wisconsin Alumni Research Foundation	Methods for the treatment of x-linked hypophosphatemia and related disorders
MX381052B (es)	2014-06-09	2025-03-12	Ultragenyx Pharmaceutical Inc	El control efectivo y eficaz del fosfato serico para una osificacion optima.
CN109432398A (zh) *	2016-03-13	2019-03-08	曹帅	一种用于治疗骨髓增生、骨癌的药物组合物及其用途
WO2018069232A1 (en)	2016-10-10	2018-04-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting the risk of having cardiac hypertrophy
CN109601477A (zh) *	2018-12-21	2019-04-12	云南农业大学	一种基于维生素d受体血液生化标记选育武定鸡的方法
CN115902234A (zh) *	2022-09-07	2023-04-04	山西农业大学	一种检测自然放牧下绵羊钙磷代谢紊乱的肝脏代谢物检测标志物组合物
CN119431500A (zh) *	2024-09-30	2025-02-14	西北农林科技大学	一种CaSR的抗原表位肽、疫苗、抗体及其应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1985003934A1 (fr)	1984-03-06	1985-09-12	Takeda Chemical Industries, Ltd.	Proteine modifiee chimiquement et son procede de preparation
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
FI884924L (fi)	1987-10-28	1989-04-29	Oncogen	Humanimmuglobulin som producerats med hybrid-dna-teknik.
JP2958019B2 (ja)	1988-05-06	1999-10-06	住友製薬株式会社	ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
CN1047086A (zh) *	1989-03-16	1990-11-21	大制药株式会社	多肽衍生物及钙代谢改善剂
US5958879A (en) *	1989-10-12	1999-09-28	Ohio University/Edison Biotechnology Institute	Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal
GEP20002180B (en)	1994-03-31	2000-07-25	Amgen Inc	Composition and Methods for Stimulating Megakaryocyte Growth and Differentiation
US6001358A (en)	1995-11-07	1999-12-14	Idec Pharmaceuticals Corporation	Humanized antibodies to human gp39, compositions containing thereof
JP2002512517A (ja) *	1997-03-25	2002-04-23	ジェネティックス・インスチチュート・インコーポレーテッド	分泌蛋白およびそれらをコードするポリヌクレオチド
CN100359015C (zh)	1998-05-18	2008-01-02	伦敦大学专科学院	多肽激素磷酸盐沉着因子
TWI255853B (en)	1998-08-21	2006-06-01	Kirin Brewery	Method for modifying chromosomes
JP2000287684A (ja)	1999-02-05	2000-10-17	Asahi Breweries Ltd	癌及び流産に関与する染色体領域９ｐ１１の塩基配列
JP3490327B2 (ja)	1999-02-19	2004-01-26	東光株式会社	スイッチング電源装置
AU3924300A (en)	1999-04-02	2000-10-23	Millennium Pharmaceuticals, Inc.	Fibroblast growth factor-20
US6596849B1 (en) *	1999-05-28	2003-07-22	Academia Sinica	Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
JP2004522402A (ja) *	1999-06-02	2004-07-29	ジェネンテック・インコーポレーテッド	同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
JP2001121527A (ja)	1999-10-29	2001-05-08	Asahi Glass Co Ltd	複合パネルおよびその製法
CA2491433A1 (en) *	1999-12-01	2001-06-07	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003516150A (ja) *	1999-12-08	2003-05-13	ジェンセット	潜在性分泌タンパク質をコードする全長ヒトｃＤＮＡ
EP1246843A1 (de) *	2000-01-05	2002-10-09	ZymoGenetics, Inc.	Neues fgf homolog zfgf12
AU2001239765A1 (en) *	2000-02-14	2001-08-27	Smith Kline Beecham Corporation	Novel compounds
AU3976701A (en) *	2000-02-15	2001-08-27	Amgen, Inc.	Fibroblast growth factor-23 molecules and uses thereof
US20060160181A1 (en)	2000-02-15	2006-07-20	Amgen Inc.	Fibroblast Growth Factor-23 molecules and uses thereof
WO2001066595A2 (en) *	2000-03-08	2001-09-13	Chiron Corporation	Human fgf-23 gene and gene expression products
AU2001245535A1 (en) *	2000-03-08	2001-09-17	Chiron Corporation	Human fgf-23 gene and gene expression products
ATE461213T1 (de)	2000-07-19	2010-04-15	Advanced Res & Tech Inst	Neuer fibroblastwachstumsfaktor (fgf23) und methoden zur verwendung
EP2233571B1 (de)	2000-08-11	2012-11-07	Kyowa Hakko Kirin Co., Ltd.	Den Phosphorsäure-Metabolismus, den Kalzium-Metabolismus, Verkalkung und den Vitamin D-Metabolismus kontrollierende Polypeptide sowie für diese kodierende DNA-Moleküle
CA2430013C (en)	2000-11-30	2011-11-22	Medarex, Inc.	Transgenic transchromosomal rodents for making human antibodies
WO2002076467A1 (en)	2001-03-22	2002-10-03	Genzyme Corporation	Compositions and methods to regulate bone and mineral metabolism
US20040171825A1 (en)	2001-04-26	2004-09-02	Lydie Bougueleret	Human fibroblast growth factor-related compositions
JP4527982B2 (ja)	2001-12-28	2010-08-18	協和発酵キリン株式会社	線維芽細胞増殖因子−２３に対する抗体
US7094551B2 (en) *	2002-09-17	2006-08-22	Zahradnik Richard J	Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23
JPWO2006078072A1 (ja)	2005-01-21	2008-06-19	キリンファーマ株式会社	キメラ非ヒト動物およびその使用
EP2054521A4 (de)	2006-10-03	2012-12-19	Novo Nordisk As	Verfahren zur reinigung von polypeptid-konjugate
US20100062984A1 (en)	2007-01-25	2010-03-11	Rajiv Kumar	Fgf-23 polypeptides
US7883705B2 (en)	2007-02-14	2011-02-08	Kyowa Hakko Kirin Co., Ltd.	Anti FGF23 antibody and a pharmaceutical composition comprising the same

2001
- 2001-08-10 EP EP10163562A patent/EP2233571B1/de not_active Expired - Lifetime
- 2001-08-10 ES ES10163562T patent/ES2398203T3/es not_active Expired - Lifetime
- 2001-08-10 AT AT01958379T patent/ATE469217T1/de not_active IP Right Cessation
- 2001-08-10 ES ES01958379T patent/ES2344679T3/es not_active Expired - Lifetime
- 2001-08-10 KR KR1020037001931A patent/KR100886276B1/ko not_active Expired - Lifetime
- 2001-08-10 TW TW090119818A patent/TWI224620B/zh not_active IP Right Cessation
- 2001-08-10 CN CNB018172962A patent/CN100387713C/zh not_active Expired - Lifetime
- 2001-08-10 AU AU2001280096A patent/AU2001280096B2/en not_active Expired
- 2001-08-10 EP EP01958379A patent/EP1310554B1/de not_active Expired - Lifetime
- 2001-08-10 CA CA2418802A patent/CA2418802C/en not_active Expired - Lifetime
- 2001-08-10 CN CNA2008100866831A patent/CN101275136A/zh active Pending
- 2001-08-10 WO PCT/JP2001/006944 patent/WO2002014504A1/ja not_active Ceased
- 2001-08-10 US US10/344,339 patent/US20040082506A1/en not_active Abandoned
- 2001-08-10 AU AU8009601A patent/AU8009601A/xx active Pending
- 2001-08-10 DE DE60142239T patent/DE60142239D1/de not_active Expired - Lifetime
- 2001-08-10 JP JP2002519632A patent/JP4799801B2/ja not_active Expired - Lifetime
2008
- 2008-12-01 US US12/325,551 patent/US7981419B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP2233571A1 (de)	2010-09-29
CA2418802C (en)	2012-10-23
WO2002014504A1 (en)	2002-02-21
DE60142239D1 (de)	2010-07-08
AU2001280096B2 (en)	2007-03-22
US20090110677A1 (en)	2009-04-30
CN1633499A (zh)	2005-06-29
EP1310554B1 (de)	2010-05-26
KR100886276B1 (ko)	2009-03-04
EP1310554A4 (de)	2005-07-13
CN101275136A (zh)	2008-10-01
ES2344679T3 (es)	2010-09-03
JP4799801B2 (ja)	2011-10-26
KR20030036685A (ko)	2003-05-09
CN100387713C (zh)	2008-05-14
ES2398203T3 (es)	2013-03-14
EP2233571B1 (de)	2012-11-07
CA2418802A1 (en)	2003-02-10
AU8009601A (en)	2002-02-25
EP1310554A1 (de)	2003-05-14
US7981419B2 (en)	2011-07-19
TWI224620B (en)	2004-12-01
US20040082506A1 (en)	2004-04-29

Legal Events

Date	Code	Title	Description
2010-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE469217T1 (de)	2010-06-15	Den phosphorsäure-metabolismus, den kalzium- metabolismus, verkalkung und den vitamin d- metabolismus kontrollierende polypeptide sowie für diese kodierende dna-moleküle
BR0208453A (pt)	2006-02-21	composições e métodos de desintoxicação de zearalenona
DE60232870D1 (de)	2009-08-20	Neue polynukleotide und polypeptide des erythropoietingens
BR0113864A (pt)	2004-06-29	ácidos nucléicos tipo kcp isolados e suas proteìnas codificadas
DE69834267D1 (de)	2006-05-24	Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen
FR2762850B1 (fr)	2000-02-11	Lactoferrines recombinantes, leurs procedes de production par les plantes ainsi que leurs utilisations
ATE478092T1 (de)	2010-09-15	Verbesserte sekretion von neublastin
PT917571E (pt)	2005-04-29	Gene relacionado com agouti
EP1017792A4 (de)	2005-04-20	Rekombinante materialien und methoden zur herstellung von limonenhydroxylasen
ATE378408T1 (de)	2007-11-15	Transformierender wachstumsfaktor beta-9 (ztgfss9) aus säugetieren
ATE455792T1 (de)	2010-02-15	Neues phosphatbindendes protein, pharmazeutische zusammensetzungen, die dieses enthalten, und verwendung davon
DE60237791D1 (de)	2010-11-04	Zytokinproteinfamilie
ATE414156T1 (de)	2008-11-15	Lipase-varianten
ATE230025T1 (de)	2003-01-15	Proteinanaloge des ldl-rezeptors und deren kodierende gene
ATE412751T1 (de)	2008-11-15	Menschliche tak1 und für diese kodierende dna
DE59410423D1 (de)	2006-01-12	Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ATE202798T1 (de)	2001-07-15	D-aminosäure-oxidase kodierendes dns-fragment
BR0209144A (pt)	2004-06-08	Composição associadas ao fator de crescimento de fibroblasto humano
DE60124380D1 (de)	2006-12-21	Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
ATE375390T1 (de)	2007-10-15	G-protein-gekoppelter rezeptor-ähnliche proteine
WO2002018536A3 (fr)	2003-01-03	Proteine bard1 tronquee, et ses applications diagnostiques et therapeutiques
EP1013665A4 (de)	2004-10-27	Neue polypeptide mit wasserkanalaktivität und dna sequenzen
DE60304332D1 (de)	2006-05-18	Hydantoinracemase
IL151211A0 (en)	2003-04-10	Compositions useful for regulating parkin gene activity
FI954889A7 (fi)	1995-11-10	Proteiini, jolla on TPO-aktiviteetti